Pre-Exposure Prophylaxis study (treated before exposed to the virus)
et al., Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-218244 (Letter)
Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxych loroquine use and immunosuppressive treatments
Small study of 152 SLE patients taking HC
Q with a phone survey for COVID-19 suggestive symptoms. There was 2 hospitalizations (group not identified) and no ICU or death cases. A similar percentage of suspected infections were reported for HC
Q users and non-HC
Q users, RR 0.96, p
There was no mortality and severity was not analyzed to determine if HC
Q treated patients fared better. No adjustment for concomitant medications or severity of SLE. Only 5 cases were PCR confirmed.
COVID-19 case, ↓3.9%, p=0.93
Please send us corrections, updates, or comments.